Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc. is a medical device company that develops extracorporeal blood purification technologies to address cancer and infectious disease disorders. The company’s portfolio includes platforms designed to enhance cancer treatments, including the ImmunePrep platform to optimize immunotherapeutic antibody delivery, ChemoPrep to improve chemotherapy delivery, and ChemoPure to lower treatment toxicity by removing off-target chemotherapy. Its lead candidate, Sigyn Therapy, is a single-use disposable device designed to extract pathogens, bacterial toxins, hepatic toxins, and inflammatory cytokines from blood plasma, targeting conditions such as viral infections, antibiotic-resistant bacteria, endotoxemia, and sepsis.

The company's principal executive offices are located in San Diego, California. Sigyn designs its therapies to deploy on existing worldwide hospital hemodialysis and continuous renal replacement therapy machine infrastructure. Its clinical development plan focuses on treating end-stage renal disease patients with endotoxemia and inflammation, while preclinical and animal evaluations have taken place in academic research facilities.

Summary of the business section of Sigyn Therapeutics's latest annual report, written by StockData.

“As of the date of this filing, we have 4 salaried employees, whose benefits include paid medical, dental, and vision coverage.”